scholarly journals Potential Applications of Microparticulate-Based Bacterial Outer Membrane Vesicles (OMVs) Vaccine Platform for Sexually Transmitted Diseases (STDs): Gonorrhea, Chlamydia, and Syphilis

Vaccines ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1245
Author(s):  
Christiane Chbib ◽  
Sarthak M. Shah ◽  
Rikhav P. Gala ◽  
Mohammad N. Uddin
Keyword(s):  
Sexually Transmitted Diseases ◽  
Outer Membrane ◽  
Pathogenic Bacteria ◽  
Outer Membrane Vesicles ◽  
Health Issue ◽  
Vaccine Platform ◽  
Sexually Transmitted ◽  
Wide Range ◽  
Particulate Form ◽  
Bacterial Outer Membrane

Sexually transmitted diseases (STDs) are a major global health issue. Approximately 250 million new cases of STDs occur each year globally. Currently, only three STDs (human papillomavirus (HPV), hepatitis A, and hepatitis B) are preventable by vaccines. Vaccines for other STDs, including gonorrhea, chlamydia, and syphilis, await successful development. Currently, all of these STDs are treated with antibiotics. However, the efficacy of antibiotics is facing growing challenge due to the emergence of bacterial resistance. Therefore, alternative therapeutic approaches, including the development of vaccines against these STDs, should be explored to tackle this important global public health issue. Mass vaccination could be more efficient in reducing the spread of these highly contagious diseases. Bacterial outer membrane vesicle (OMV) is a potential antigen used to prevent STDs. OMVs are released spontaneously during growth by many Gram-negative bacteria. They present a wide range of surface antigens in native conformation that possess interesting properties such as immunogenicity, adjuvant potential, and the ability to be taken up by immune cells, all of which make them an attractive target for application as vaccines against pathogenic bacteria. The major challenge associated with the use of OMVs is its fragile structure and stability. However, a particulate form of the vaccine could be a suitable delivery system that can protect the antigen from degradation by a harsh acidic or enzymatic environment. The particulate form of the vaccine can also act as an adjuvant by itself. This review will highlight some practical methods for formulating microparticulate OMV-based vaccines for STDs.

scholarly journals Bacterial outer membrane vesicles engineered with lipidated antigens as a platform for Staphylococcus aureus vaccine

2019 ◽  
Vol 116 (43) ◽  
pp. 21780-21788 ◽  
Author(s):  
Carmela Irene ◽  
Laura Fantappiè ◽  
Elena Caproni ◽  
Francesca Zerbini ◽  
Andrea Anesi ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Outer Membrane ◽  
Membrane Vesicles ◽  
Outer Membrane Vesicles ◽  
Vaccine Platform ◽  
Transport Pathway ◽  
Protective Antigens ◽  
Tlr4 Agonist ◽  
Engineering Strategy ◽  
Bacterial Outer Membrane

Bacterial outer membrane vesicles (OMVs) represent an interesting vaccine platform for their built-in adjuvanticity and simplicity of production process. Moreover, OMVs can be decorated with foreign antigens using different synthetic biology approaches. However, the optimal OMV engineering strategy, which should guarantee the OMV compartmentalization of most heterologous antigens in quantities high enough to elicit protective immune responses, remains to be validated. In this work we exploited the lipoprotein transport pathway to engineer OMVs with foreign proteins. Using 5 Staphylococcus aureus protective antigens expressed in Escherichia coli as fusions to a lipoprotein leader sequence, we demonstrated that all 5 antigens accumulated in the vesicular compartment at a concentration ranging from 5 to 20% of total OMV proteins, suggesting that antigen lipidation could be a universal approach for OMV manipulation. Engineered OMVs elicited high, saturating antigen-specific antibody titers when administered to mice in quantities as low as 0.2 μg/dose. Moreover, the expression of lipidated antigens in E. coli BL21(DE3)ΔompAΔmsbBΔpagP was shown to affect the lipopolysaccharide structure, with the result that the TLR4 agonist activity of OMVs was markedly reduced. These results, together with the potent protective activity of engineered OMVs observed in mice challenged with S. aureus Newman strain, makes the 5-combo-OMVs a promising vaccine candidate to be tested in clinics.

scholarly journals Bioengineering bacterial outer membrane vesicles as vaccine platform

2017 ◽  
Vol 35 (5) ◽  
pp. 565-574 ◽  
Author(s):  
Matthias J.H. Gerritzen ◽  
Dirk E. Martens ◽  
René H. Wijffels ◽  
Leo van der Pol ◽  
Michiel Stork
Keyword(s):  
Outer Membrane ◽  
Membrane Vesicles ◽  
Outer Membrane Vesicles ◽  
Vaccine Platform ◽  
Bacterial Outer Membrane

scholarly journals Bacterial Outer Membrane Vesicles Provide Broad-Spectrum Protection against Influenza Virus Infection via Recruitment and Activation of Macrophages

2019 ◽  
Vol 11 (4) ◽  
pp. 316-329 ◽  
Author(s):  
Eun-Hye Bae ◽  
Sang Hwan Seo ◽  
Chang-Ung Kim ◽  
Min Seong Jang ◽  
Min-Suk Song ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Virus Infection ◽  
Protective Effect ◽  
Outer Membrane ◽  
Lethal Dose ◽  
Influenza Virus Infection ◽  
Outer Membrane Vesicles ◽  
Type I ◽  
Wide Range ◽  
Bacterial Outer Membrane

Influenza A virus (IAV) poses a constant worldwide threat to human health. Although conventional vaccines are available, their protective efficacy is type or strain specific, and their production is time-consuming. For the control of an influenza pandemic in particular, agents that are immediately effective against a wide range of virus variants should be developed. Although pretreatment of various Toll-like receptor (TLR) ligands have already been reported to be effective in the defense against subsequent IAV infection, the efficacy was limited to specific subtypes, and safety concerns were also raised. In this study, we investigated the protective effect of an attenuated bacterial outer membrane vesicle ­harboring modified lipid A moiety of lipopolysaccharide (fmOMV) against IAV infection and the underlying mechanisms. Administration of fmOMV conferred significant protection against a lethal dose of pandemic H1N1, PR8, H5N2, and highly pathogenic H5N1 viruses; this broad antiviral activity was dependent on macrophages but independent of neutrophils. fmOMV induced recruitment and activation of macrophages and elicited type I IFNs. Intriguingly, fmOMV showed a more significant protective effect than other TLR ligands tested in previous reports, without exhibiting any adverse effect. These results show the potential of fmOMV as a prophylactic agent for the defense against influenza virus infection.

Engineering multi-functional bacterial outer membrane vesicles as modular nanodevices for biosensing and bioimaging

2017 ◽  
Vol 53 (54) ◽  
pp. 7569-7572 ◽  
Author(s):  
Qi Chen ◽  
Sharon Rozovsky ◽  
Wilfred Chen
Keyword(s):  
Outer Membrane ◽  
Membrane Vesicles ◽  
Outer Membrane Vesicles ◽  
Signal Generation ◽  
Antigen Binding ◽  
One Pot ◽  
One Pot Synthesis ◽  
Wide Range ◽  
Bacterial Outer Membrane ◽  
Synthesis Approach

We report here a one-pot synthesis approach to engineer multi-functionalized OMV-based sensors for both antigen binding and signal generation. A virtually unlimited combination of capturing and reporting moieties can be created for a wide range of biosensing and bioimaging applications.

scholarly journals Bacterial Outer Membrane Vesicles as Nano‐Scale Bioreactors: A Fatty Acid Conversion Case Study

ChemCatChem ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4080-4086
Author(s):  
Ji‐Won Song ◽  
Yoonjin Baeg ◽  
Ha‐Yeon Jeong ◽  
Jinwon Lee ◽  
Deok‐Kun Oh ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Outer Membrane ◽  
Membrane Vesicles ◽  
Outer Membrane Vesicles ◽  
Nano Scale ◽  
Bacterial Outer Membrane

scholarly journals Proteome‐minimized outer membrane vesicles from Escherichia coli as a generalized vaccine platform

2021 ◽  
Vol 10 (4) ◽  
Author(s):  
Ilaria Zanella ◽  
Enrico König ◽  
Michele Tomasi ◽  
Assunta Gagliardi ◽  
Luca Frattini ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Outer Membrane ◽  
Membrane Vesicles ◽  
Outer Membrane Vesicles ◽  
Vaccine Platform

scholarly journals Aggregatibacter actinomycetemcomitans Leukotoxin Is Delivered to Host Cells in an LFA-1-Indepdendent Manner When Associated with Outer Membrane Vesicles

Toxins ◽  
2018 ◽  
Vol 10 (10) ◽  
pp. 414 ◽  
Author(s):  
Justin Nice ◽  
Nataliya Balashova ◽  
Scott Kachlany ◽  
Evan Koufos ◽  
Eric Krueger ◽  
...  
Keyword(s):  
Outer Membrane ◽  
Membrane Vesicles ◽  
Aggregatibacter Actinomycetemcomitans ◽  
Aggressive Periodontitis ◽  
Outer Membrane Vesicles ◽  
Host Cells ◽  
Type I ◽  
Outer Membranes ◽  
Independent Mechanism ◽  
Bacterial Outer Membrane

The Gram-negative bacterium, Aggregatibacter actinomycetemcomitans, has been associated with localized aggressive periodontitis (LAP). In particular, highly leukotoxic strains of A. actinomycetemcomitans have been more closely associated with this disease, suggesting that LtxA is a key virulence factor for A. actinomycetemcomitans. LtxA is secreted across both the inner and outer membranes via the Type I secretion system, but has also been found to be enriched within outer membrane vesicles (OMVs), derived from the bacterial outer membrane. We have characterized the association of LtxA with OMVs produced by the highly leukotoxic strain, JP2, and investigated the interaction of these OMVs with host cells to understand how LtxA is delivered to host cells in this OMV-associated form. Our results demonstrated that a significant fraction of the secreted LtxA exists in an OMV-associated form. Furthermore, we have discovered that in this OMV-associated form, the toxin is trafficked to host cells by a cholesterol- and receptor-independent mechanism in contrast to the mechanism by which free LtxA is delivered. Because OMV-associated toxin is trafficked to host cells in an entirely different manner than free toxin, this study highlights the importance of studying both free and OMV-associated forms of LtxA to understand A. actinomycetemcomitans virulence.

Sign in / Sign up

Export Citation Format

Share Document